Author

E. Serbinowski

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 2 Pathology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Organism:human· 3 Approach:experimental assay· 2 Assay:bulk RNA-seq· 1 Research Focus:cancer & tumor microenvironment· 1 Research Focus:cell type annotation· 1 Research Focus:differential expression· 1 Assay:flow cytometry· 1 Research Focus:gene regulatory network inference· 1

Frequent Co-Authors

J. D. Lathia· 3 shared D. Bayik· 2 shared D. J. Silver· 2 shared J. S. Hale· 2 shared T. Alban· 2 shared A. Berezovsky· 1 shared A. G. Alvarado· 1 shared A. Lauko· 1 shared

Activity by Year

2018-2019 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 31 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersCancer Biology

J. D. Lathia

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

Cholangiocarcinoma presents a distinct myeloid-derived suppressor cell signature compared to other hepatobiliary cancers

D. Bayik, A. Lauko, G. A. Roversi, E. Serbinowski, L.-A. Acevedo-Moreno, C. Lanigan, M. Orujov, A. Lo, T. Alban, D. J. Silver, J. M. Brown, D. S. Allende, F. N. Aucejo, J. D. Lathia

The paper identifies a distinct myeloid-derived suppressor cell (MDSC) signature in cholangiocarcinoma (CCA) compared to other hepatobiliary cancers, linking MDSC levels to disease outcomes and potential therapeutic targets.

bioRxiv · Dec 11, 2019 · PreprintPathology

Global immune fingerprinting in glioblastoma reveals immune-suppression signatures associated with prognosis

T. J. Alban, A. G. Alvarado, M. D. Sorensen, D. Bayik, J. Volovetz, E. Serbinowski, E. Mulkearns-Hubert, M. Sinyuk, J. S. Hale, G. R. Onzi, M. McGraw, P. Huang, M. M. Grabowski, C. A. Wathen, T. Radivoyevitch, , J. D. Lathia

The paper identifies immune-suppression signatures in glioblastoma (GBM) patients, showing elevated myeloid-derived suppressor cells (MDSCs) linked to poor prognosis and reduced survival.

bioRxiv · May 11, 2018Cancer Biology

Development of a Cx46 targeting strategy for cancer stem cells

E. E. Mulkearns-Hubert, L. A. Torre-Healy, D. J. Silver, J. T. Eurich, E. Serbinowski, M. Hitomi, J. Zhou, B. Przychodzen, R. Zhang, S. A. Sprowls, J. S. Hale, T. Alban, A. Berezovsky, B. A. Bell, P. R. Lockman, , J. D. Lathia

This study identifies clofazimine as a Cx46 inhibitor that targets glioblastoma cancer stem cells by disrupting gap junction communication, enhancing the efficacy of temozolomide.

bioRxiv · Mar 26, 2018Cancer Biology